18 years of historical data (2007–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ADMA Biologics, Inc. trades at 19.2x earnings, 9% below its 5-year average of 21.2x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 19%. On a free-cash-flow basis, the stock trades at 33.7x P/FCF, 78% below the 5-year average of 151.5x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.7B | $4.2B | $1.0B | $768M | $197M | $168M | $217M | $108M | $73M | $62M | $84M |
| Enterprise Value | $3.7B | $4.2B | $1.1B | $836M | $249M | $210M | $275M | $129M | $73M | $73M | $89M |
| P/E Ratio → | 19.22 | 21.17 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.70 | 9.79 | 3.92 | 4.98 | 2.43 | 3.98 | 7.41 | 6.36 | 3.23 | 5.84 | 11.71 |
| P/B Ratio | 10.86 | 11.96 | 7.49 | 5.05 | 1.39 | 1.90 | 8.30 | 5.46 | 1.82 | — | 102.35 |
| P/FCF | 33.71 | 37.91 | 265.09 | — | — | — | — | — | — | — | — |
| P/OCF | 31.27 | 35.17 | 115.04 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
ADMA Biologics, Inc.'s enterprise value stands at 25.1x EBITDA, 23% below its 5-year average of 32.5x. The Healthcare sector median is 13.8x, placing the stock at a 81% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.74 | 4.27 | 5.42 | 3.07 | 4.97 | 9.38 | 7.62 | 3.22 | 6.81 | 12.44 |
| EV / EBITDA | 25.10 | 28.24 | 36.79 | — | — | — | — | — | — | — | — |
| EV / EBIT | 26.55 | 29.73 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 37.71 | 288.67 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
ADMA Biologics, Inc. earns an operating margin of 32.6%. Operating margins have expanded from -25.5% to 32.6% over the past 3 years, signaling improving operational efficiency. Return on equity of 81.6% is exceptionally high. ROIC of 37.7% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.5% | 51.5% | 34.4% | 22.9% | 1.4% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% | 39.9% |
| Operating Margin | 32.6% | 32.6% | 8.4% | -25.5% | -72.1% | -153.8% | -141.1% | -354.9% | -172.7% | -162.6% | -216.1% |
| Net Profit Margin | 46.4% | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% | -250.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 81.6% | 81.6% | -19.7% | -45.0% | -62.5% | -132.4% | -210.1% | -218.8% | -243.9% | — | -526.2% |
| ROA | 48.3% | 48.3% | -8.3% | -21.1% | -29.6% | -45.3% | -44.7% | -66.8% | -66.5% | -82.3% | -70.6% |
| ROIC | 37.7% | 37.7% | 7.3% | -14.3% | -27.1% | -45.5% | -49.5% | -111.0% | -128.0% | -216.7% | -235.3% |
| ROCE | 39.0% | 39.0% | 7.4% | -14.2% | -26.9% | -43.2% | -43.1% | -67.8% | -70.8% | -108.4% | -73.0% |
Solvency and debt-coverage ratios — lower is generally safer
ADMA Biologics, Inc. carries a Debt/EBITDA ratio of 0.6x, which is very conservative (82% below the sector average of 3.1x). The company holds a net cash position — cash of $103M exceeds total debt of $82M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 10.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 1.05 | 1.02 | 0.73 | 1.11 | 3.23 | 2.24 | 1.07 | — | 19.16 |
| Debt / EBITDA | 0.56 | 0.56 | 4.72 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | 0.67 | 0.45 | 0.37 | 0.47 | 2.21 | 1.09 | -0.00 | — | 6.44 |
| Net Debt / EBITDA | -0.14 | -0.14 | 3.01 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.19 | 23.58 | — | — | — | — | — | — | — | — |
| Interest Coverage | 9.98 | 9.98 | 0.86 | -2.04 | -4.47 | -5.42 | -4.61 | -10.92 | -11.96 | -7.74 | -8.42 |
Net cash position: cash ($103M) exceeds total debt ($82M)
Short-term solvency ratios and asset-utilisation metrics
ADMA Biologics, Inc.'s current ratio of 5.97x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.90x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.89x to 5.97x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.97 | 5.97 | 5.16 | 6.89 | 6.87 | 7.71 | 6.12 | 4.63 | 6.69 | 1.93 | 5.05 |
| Quick Ratio | 2.90 | 2.90 | 1.69 | 2.73 | 2.77 | 3.62 | 2.34 | 2.69 | 5.35 | 1.48 | 4.23 |
| Cash Ratio | 1.86 | 1.86 | 1.03 | 2.20 | 1.68 | 2.80 | 1.91 | 2.36 | 4.57 | 1.36 | 3.99 |
| Asset Turnover | — | 0.87 | 0.78 | 0.44 | 0.29 | 0.20 | 0.23 | 0.19 | 0.21 | 0.45 | 0.30 |
| Inventory Turnover | 1.22 | 1.22 | 0.98 | 0.73 | 0.64 | 0.75 | 0.74 | 2.27 | 2.31 | 1.27 | 1.25 |
| Days Sales Outstanding | — | 42.79 | 38.76 | 36.73 | 128.86 | 114.44 | 43.15 | 29.92 | 62.22 | 34.85 | 47.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ADMA Biologics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 5.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.2% | 4.7% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 3.0% | 2.6% | 0.4% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $243M | $224M | $198M | $140M | $86M | $54M | $45M | $23M | $12M | $10M |
Compare ADMA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ADMAYou | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| TBPH | $925M | -15.9 | — | — | 100.0% | -72.9% | -29.0% | -17.2% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 18 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ADMA stacks up against sector leader United Therapeutics Corporation.
Start ComparisonADMA Biologics, Inc.'s current P/E ratio is 19.2x. The historical average is 21.2x.
ADMA Biologics, Inc.'s current EV/EBITDA is 25.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 32.5x.
ADMA Biologics, Inc.'s return on equity (ROE) is 81.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -111.6%.
Based on historical data, ADMA Biologics, Inc. is trading at a P/E of 19.2x. Compare with industry peers and growth rates for a complete picture.
ADMA Biologics, Inc. has 51.5% gross margin and 32.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
ADMA Biologics, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.